Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price target hoisted by equities researchers at Craig Hallum from $23.00 to $26.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s price target indicates a potential upside of 78.45% from the company’s current price.

Several other brokerages have also commented on ETON. B. Riley reaffirmed a “buy” rating and set a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON traded down $0.11 during mid-day trading on Wednesday, reaching $14.57. 105,229 shares of the stock were exchanged, compared to its average volume of 157,623. The business’s fifty day simple moving average is $15.45 and its 200 day simple moving average is $11.42. The stock has a market capitalization of $379.56 million, a PE ratio of -66.46 and a beta of 1.37. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. On average, analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Institutional Trading of Eton Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eton Pharmaceuticals in the third quarter valued at $54,000. Tower Research Capital LLC TRC purchased a new position in Eton Pharmaceuticals in the 4th quarter valued at about $86,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the third quarter valued at about $90,000. Jefferies Financial Group Inc. purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth about $133,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $147,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.